Galegenimab - Genentech
Alternative Names: FHTR2163; RG-6147; RO-7171009Latest Information Update: 05 Nov 2023
At a glance
- Originator Genentech
- Class Eye disorder therapies; Immunoglobulin fragments; Monoclonal antibodies
- Mechanism of Action High-temperature requirement A serine peptidase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dry macular degeneration
Most Recent Events
- 14 Nov 2022 Genentech terminates a phase II trial in Dry macular degeneration (In the elderly, In adults) in USA (Intravitreous) as the benefit to risk balance analysis did not support its further use (NCT04607148)
- 27 Oct 2022 Genentech terminates a phase II trial in Dry macular degeneration (In the elderly, In adults) in USA (Intravitreous) as the benefit to risk balance analysis did not support its further use (NCT03972709)
- 19 Oct 2022 Discontinued - Phase II trial for Dry macular degeneration (In adults, In the elderly) in USA (Intravitreal, Injection) (Roche pipeline, October 2022)